Menu
About Us
Company Overview
Corporate Culture
Manufacturing Base
MAH
Drug Development to Commercialization
Milestones
Code of Business Ethics
Services
Services
Providing reliable CDMO solutions with excellent quality and professional services
ADC Platform
Overview
ADC R&D Service Platform
Conjugation Process
Development
and Optimization
Drug Product
Formulation and
Lyophilization Process
Analysis Services
Antibody Manufacturing
ADC Drug Substance
Manufacturing
Lyophilized Drug
Product Manufacture
Protein/Antibody Platform
Overview
Cell Culture
Process Development
Purification Process
Development
Drug Product
Formulation and
Lophilization Process
Analysis Services
GMP Manufacturing
Overview
Drug Substance
Manufacturing
Drug Product
Manufacturing
Process Characterization
/Process Validation
Technology Transfer
Overview
Technology Transfer
Quality
Overview
Quality Control
Quality Assurance
Regulatory Affairs
Overview
Service and Advantages
Investor Relations
Company Profile
Corporate Governance
Information Disclosure
Presentations & Webcasts
Investor Relations Query
News & Events
News
Events
Media Attention
Partner News
Resources
Technical Articles
Download Center
Join Us
Members of BioDlink
Join in BioDlink
Contact Us
EN
繁體
简体
EN
繁體
简体
Home
＜
Investor Relations
Investor Relations
Company Profile
Corporate Governance
Information Disclosure
Announcements and Circulars
Financial Reports and ESG Reports
The Listed Files
Presentations & Webcasts
Investor Relations Query
Listing document
Global Offering
global release
Other documents
Documents on display-【001】-1875 Articles (EN)
Documents on display-【002】-1875 Articles (CN)
Documents on display-【003】-2268-Articles (EN)
Documents on display-【004】-2268-Articles (CN)
Documents on display-【005】-2022 Annual Report (ENG)
Documents on display-【006】- 2022 Annual Report (CHI)
Documents on display-【007】- 2023 Annual Report (ENG) - 001
Documents on display-【007】- 2023 Annual Report (ENG) - 002
Documents on display-【008】- 2023 Annual Report (CHI) - 001
Documents on display-【008】- 2023 Annual Report (CHI) - 002
Documents on display-【009】- 2024 Annual Report (ENG)
Documents on display-【010】- 2024 Annual Report (CHI)
Documents on display-【011】- Letter from Citi
Documents on display-【012】- Letter from the Board
Documents on display-【013】- Letter from the Independent Board Committee
Documents on display-【014】- Letter from the Independent Financial Adviser
Documents on display-【015】- Irrevocable Undertaking (Vivo Capital)
Documents on display-【016】- Irrevocable Undertaking (Vivo Suzhou)
Documents on display-【017】- Irrevocable Undertaking (Center Laboratories)
Documents on display-【018】- Irrevocable undertaking (Advantech)
Documents on display-【019】-Irrevocable Undertaking (Chengwei Evergreen Capital)
Documents on display-【020】-List of dealings by IU Shareholders
Documents on display-【021】- Consent Letter from the Independent Financial Adviser
Documents on display-【022】-Consent Letter from Citi
Documents on display-【023】-Composite Document (Eng)
Documents on display-【024】-Composite Document (Chi)
Documents on display-【025】-Form of Acceptance (Share Offer)
Documents on display-【026】-Form of Acceptance (Option Offer)
White_Application_Form
Green_Application_Form
Yellow_Application_Form
Offer_for_Subscription
Procedures_for_Shareholders_to_Propose_a_Person_for_Election_as_a_Director_of_the_Company
The module is under construction